Clinical Study

Investigation of Antiphosphatidyl-Serine Antibody and Antiphosphatidyl-Inositol Antibody in Ischemic Stroke Patients

Hirohisa Okuma,1 Yasuhisa Kitagawa,2 and Shigeharu Takagi3

1 Department of Neurology, Tokai University Tokyo Hospital, Tokyo 151-0053, Japan
2 Department of Neurology, Tokai University Hachioji Hospital, Tokyo 192-0032, Japan
3 Department of Neurology, Tokai University School of Medicine, Kanagawa 259-1193, Japan

Correspondence should be addressed to Hirohisa Okuma, ookuma@tok.u-tokai.ac.jp

Received 27 August 2010; Accepted 9 November 2010

Academic Editor: Stuart Mannering

Copyright © 2010 Hirohisa Okuma et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Antiphospholipid syndrome is characterized by arterial or venous thrombosis and the presence of antiphospholipid antibodies (aPL). We measured β2-GPI aCL, IgG aCL, LA, antiphosphatidyl-serine antibody (PS), and antiphosphatidyl-inositol antibody (PI) in each patient at one month after the onset of stroke. In addition, carotid artery echography was performed in patients positive for PI or PS. Among the 250 patients, 13.6% (34/250) were positive for either PI or PS, and 6.8% (17/250) were positive for both. Carotid artery echography performed on these 34 patients showed that the frequencies of increased intimal-medial thickness (IMT) of 1.1 mm or more, plaque, and carotid artery stenosis of 50% or more were all significantly higher in patients positive for antinuclear antibody than those negative for the antibody (P < .05). PI and PS are associated with antinuclear antibody and precipitation of atherosclerosis. Ischemic stroke patients with SLE frequently showed a variety of antiphospholipid-protein antibodies.

1. Introduction

In cerebrovascular disorders with an underlying immune abnormality, antiphospholipid antibodies, of which there are numerous types, are the leading cause of thrombosis in the absence of acquired risk factors [1]. Cardiolipin was the first identified antigen for antiphospholipid antibodies, and other anionic phospholipids were subsequently recognised as antigens. It is now considered that proteins that bind to phospholipids play an important role in thrombogenesis. Among these proteins, β2-glycoprotein is the most important [2–4]. Known antigens to antiphospholipid antibodies include cardiolipin, the anionic phospholipids phosphatidylycerine and phosphatidylglycerol, and neutral phosphatidyethanolamine. There is also a group of proteins, including prothrombin, annexin V, protein C, protein S, low-molecular-weight kininogen, and factor XI, that bind to phospholipids and are known as antiphospholipid-protein antigens [5]. Recently, the antiprothrombin antibody has been under investigation as a possible new autoantibody. This antibody binds to prothrombin in the presence of cardiolipin and phosphatidylserine [6]. To define and characterise these antibodies, we studied their prevalence rates in patients who had experienced cerebral infarction, and investigated the relationships among the antibodies.

2. Materials and Methods

This study involved 250 patients, 155 males and 95 females (average age 72 years), with cerebral infarction who visited our hospitals. Of these patients, one male and four females (average age 39 years) had systemic lupus erythematosus (SLE) as an underlying disease. Levels of antiphospholipid antibodies, including β2-glycoprotein I-dependent anticardiolipin antibody (β2-GPI aCL), IgG anticardiolipin antibody (IgG aCL), lupus anticoagulant (LA), antiphosphatidyl-serine antibody (PS), and antiphosphatidyl-inositol antibody (PI), were determined in the 250 patients. The level of antinuclear antibody was also measured in patients positive for PI or PS. Measurement of PI...
and PS is an enzyme-linked immunosorbent assay (ELISA) using a solid-phase method. More specifically, 100 μL of L-α-phosphatidyl-L-serine or L-α-phosphatidyl-L-inositol and the 50-fold diluted serum to be tested are added to microplates preprocessed with 5 μg/mL of protamine sulfate to allow them to react for 90 minutes at 37°C. A buffer (0.01 MPBS and 0.05% Tween) is used to clean unreacted substances, to which 100 μL of peroxidase-labelled antihuman IgG antibody is then added to allow them to react for 90 minutes at room temperature. A buffer is used to clean unreacted labelled antibodies, to which 0.4 mg/mL of o-phenylenediamine solution with 0.012% hydrogen peroxide added is then dispensed in 100-μL aliquots to leave them standing for 20 minutes at room temperature. After that, 2.5 M sulfuric acid was added to them to stop the reaction for the measurement of their absorbance at 490 nm. Results were expressed as the cut-off index, which is equal to the ratio of the absorbance of the serum to be tested to that of a healthy person, with an absorbance of 1.0 or more defined as positive. In addition, carotid artery echography was performed in patients positive for PI or PS. Assessment of the presence of various antibodies was carried out in patients in the chronic stage, at least 1 month after the onset of cerebral infarction. This study was analyzed statistically using t-test.

3. Results

The prevalence rates of the antibodies in the 250 patients with cerebral infarction. They were 2.8% (7/250) for β2-GPI aCL, 12.0% (30/250) for IgG aCL, 9.2% (23/250) for LA, 9.6% (24/250) for PS, and 8.8% (22/250) for PI. Patients aged 50 years or under accounted for 5.2% of the 250 patients (13/250), and of these, 5 had underlying SLE (1 male and 4 females, average age 39). Of these 5 patients, 80% (4/5) were positive for both β2-GPI aCL and LA, and 40% were positive for PI or PS as well as β2-GPI aCL or LA. One was negative for β2-GPI aCL and LA and positive for PI and PS (Table 1).

Among the 250 patients, 13.6% (34/250) were positive for either PI or PS, and 6.8% (17/250) were positive for both. Of the 34 patients positive for either PI or PS, 8.8% (3/34) were positive for LA, and 8.8% (3/34) were positive for b2-GPI aCL, with 70.6% (24/34) positive for antinuclear antibody.

Of the 24 patients positive for antinuclear antibody, 50% (12/24) had lacunar infarction, and 41.2% (10/24) had atherothrombotic cerebral infarction. Of the patients with lacunar infarction, 12.5% (3/24) were positive for PI only, 16.7% (4/24) were positive for PS only, and 20.8% (5/24) were positive for both PI and PS. Of the patients with atherothrombotic cerebral infarction, 4.2% (1/24) were positive for PI only, 4.2% (1/24) were positive for PS only, and 33.3% (8/24) were positive for both PI and PS. The incidence of cardiogenic cerebral embolism in patients positive for antinuclear antibody was 8.3% (2/24): 1 was positive for PS only, and 1 was positive for both PI and PS. One patient was positive for all of PI, PS, β2-GPI aCL, LA, and antinuclear antibody, and this patient had atherothrombotic cerebral infarction (Table 2).

Of the 34 patients positive for PI or PS, 79.2% were positive for antinuclear antibody, suggesting that PI and PS may be related to the antinuclear antibody. Carotid artery

Table 1: Antiphospholipid-protein antibodies in stroke patients with SLE.

| Case | Age/Gender | β2-GPI aCL | IgG-aCL | LA | PI | PS |
|------|------------|------------|---------|----|----|----|
| 1    | 50 M       | +          | –       | +  | –  | +  |
| 2    | 41 F       | +          | –       | +  | –  | –  |
| 3    | 29 F       | +          | +       | –  | +  | –  |
| 4    | 31 F       | +          | +       | +  | +  | +  |
| 5    | 46 F       | –          | –       | +  | +  | –  |

Table 2: Clinical and laboratory findings in patients with PI and PS.

| Case | Age/Gender | PI     | PS     | β2-GPlaCL | ANA  | Type of stroke |
|------|------------|--------|--------|-----------|------|----------------|
| 1    | 68 H       | 0.5    | 1.4    | (−)       | D80× | L              |
| 2    | 63 M       | 1.1    | 1.1    | (−)       | D80× | C              |
| 3    | 72 M       | 2.1    | 0.6    | (−)       | (−)  | L              |
| 4    | 58 M       | 1.9    | 1.7    | (−)       | D80× | A              |
| 5    | 64 F       | 1.6    | 1.5    | (−)       | D80× | L              |
| 6    | 78 M       | 0.8    | 1.3    | (−)       | D40× | L              |
| 7    | 48 F       | 1.9    | 1.5    | (−)       | D640 | L              |
| 8    | 66 M       | 1.0    | 0.5    | (−)       | (−)  | L              |
| 9    | 43 M       | 1.8    | 0.7    | (−)       | N160 | A              |
| 10   | 71 M       | 1.1    | 1.0    | (−)       | SP40 | L              |
| 11   | 70 M       | 1.9    | 0.8    | (−)       | D80× | A              |
| 12   | 60 M       | 1.4    | 1.1    | (−)       | D40× | A              |
| 13   | 64 M       | 1.1    | 0.9    | (−)       | SP40 | L              |
| 14   | 49 M       | 2.1    | 0.9    | (−)       | LA+  | (−) A          |
| 15   | 58 M       | 1.5    | 1.4    | (−)       | D+N40| A              |
| 16   | 68 F       | 1.5    | 1.2    | (−)       | D160 | L              |
| 17   | 53 F       | 8.1    | 1.1    | (−)       | SP80 | A              |
| 18   | 72 F       | 1.5    | 1.1    | (−)       | SP80 | L              |
| 19   | 71 M       | 1.0    | 0.7    | (−)       | (−)  | L              |
| 20   | 73 F       | 1.3    | 0.8    | (−)       | SP80 | L              |
| 21   | 64 F       | 1.1    | 1.3    | (−)       | D640 | A              |
| 22   | 81 M       | 1.0    | 0.9    | (−)       | SP40 | L              |
| 23   | 76 M       | 1.3    | 1.6    | (−)       | SP40 | A              |
| 24   | 80 M       | 1.3    | 1.3    | (−)       | D80× | A              |
| 25   | 83 F       | 0.7    | 1.4    | (−)       | (−)  | A              |
| 26   | 44 M       | 2.1    | 1.3    | (−)       | D2560| C              |
| 27   | 52 M       | 2.1    | 2.9    | (−)       | SP40 | A              |
| 28   | 79 M       | 0.7    | 1.1    | (−)       | (−)  | L              |
| 29   | 76 F       | 0.8    | 1.1    | (−)       | D80× | L              |
| 30   | 65 M       | 0.8    | 1.1    | (−)       | SP40 | L              |
| 31   | 63 F       | 0.5    | 1.8    | (−)       | SP40 | C              |
| 32   | 31 M       | 1.4    | 1.3    | (+)       | LA+  | D320 A         |
| 33   | 50 M       | 0.5    | 1.1    | (+)       | LA+  | (−) A          |
| 34   | 46 F       | 5.2    | 7.6    | (−)       | SP80 | A              |

L: lacunar infarction, A: atherothrombotic infarction, C: cardiogenic embolism D: diffuse pattern, SP: speckled pattern, and N: nucleolar pattern.
Table 3: Carotid artery echography findings of PI or PS positive patients.

| IMT ≥ 1.1 mm | Plaque positive | Carotid artery stenosis ≥50% | Carotid artery stenosis <50% |
|---------------|-----------------|------------------------------|-------------------------------|
| 48%           | 48%             | 62%                          | 31%                           |
| P < .05       | P < .05         | P < .05                      |                               |

echography performed on these 34 patients showed that the frequencies of increased intimal-medial thickness (IMT) of 1.1 mm or more, plaque, and carotid artery stenosis of 50% or more were all significantly higher in patients positive for antinuclear antibody than those negative for the antibody (P < .05) (Table 3).

4. Discussion

Previous reports have suggested that the presence of antiphospholipid antibody is a risk factor for cerebral infarction in those aged under 45 or 50 years [7]. The Antiphospholipid Antibodies in Stroke Study (APASS) [8] reported that in patients with antiphospholipid antibody, the risk of cerebral infarction was 2.31 times higher than in those negative for the antibody, and Brey et al. [9] reported that in patients with antiphospholipid antibody, the prevalence rates of the antiphospholipid antibodies aCL and LA, PI and PS were higher in patients aged 50 or more than those negative for the antibody, and ACLA patients, one with habitual abortion and the other who developed recurrent deep thrombophlebitis three times, and administered it to pregnant mice to observe various parameters. In this experiment, the administration of IgG PS to mice with immature placentas and fetuses within 9 weeks of gestation caused prolonged aPTT, thrombocytopenia, increases in placental death of 40% to 50%, and decreases in the mean weights of placentas and fetuses. Based on the results, they concluded that PS could form APS features independently on an experimental basis and suggested that it was important to check for the presence of PS in actual APS patients even if aCL was negative. It is believed that this report supports our results that PS and PI may be risk factors for juvenile cerebral infarction. Results of carotid artery echography in patients positive for PI or PS suggested that these two antibodies are associated with the promotion of arteriosclerosis.

No significant difference in the type of cerebral infarction was observed in patients positive for antinuclear antibody, but patients positive for both PI and PS tended to have atherothrombotic cerebral infarction.

Thus, we consider that PS and PI, as well as β2-GPI aCL and LA, are important in screening for antiphospholipid antibody syndrome and should be regarded as antibodies associated with cerebral infarction [14]. It remains controversial whether the presence of antiphospholipid antibody is associated with an increased risk of recurrent cerebral infarction. The APASS [15] in 1990 found that the incidence of recurrent cerebral infarction was 9.4% and that of TIA was 6.3% over an average observation period of 1.4 years, while Levine et al. [16] reported in 1992 that cerebral infarction and TIA recurred at a high incidence of 35% over an average observation period of 1.2 years. On the other hand, Tanne et al. [17] suggested that the presence of antiphospholipid antibody is not a risk factor for recurrent cerebral infarction. Further work is needed to resolve the issue, and our follow-up study of recurrent cerebral infarction in patients positive for antiphospholipid antibodies is under way.

The present results suggest that antiphospholipid antibodies should be regarded as a risk factor for juvenile cerebral infarction and that PS and PI, in addition to β2-GPI aCL and LA, should be included in the routine tests conducted in patients with cerebral infarction of unknown cause.

Antiphospholipid antibody is a risk factor for cerebral infarction, especially in SLE patients, and in the younger population. PS and PI, in addition to β2-GPI aCL and LA, are important in screening for antiphospholipid antibody syndrome and appear to be associated with cerebral infarction. And antinuclear antibody is detected at higher frequency in patients with cerebral infarction who are positive for PS and PI.

References

[1] Y. Kitagawa, “Antiphospholipid antibodies syndrome and ischemic stroke,” Annual Review, vol. 1, pp. 139–151, 2004.
[2] M. Galli, P. Comfurius, C. Maassen et al., “Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor,” The Lancet, vol. 335, no. 8705, pp. 1544–1547, 1990.
[3] E. Matsuura, Y. Igarashi, T. Yasuda, D. A. Triplett, and T. Koike, “Anticardiolipin antibodies recognize β2-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface,” Journal of Experimental Medicine, vol. 179, no. 2, pp. 457–462, 1994.
[4] T. Koike and E. Matsuura, “Anti-β-glycoprotein I antibody: specificity and clinical significance,” *Lupus*, vol. 5, no. 5, pp. 378–380, 1996.

[5] D. Tanne, D. A. Triplett, and S. R. Levine, “Antiphospholipid-protein antibodies and ischemic stroke: not just cardiolipin any more,” *Stroke*, vol. 29, no. 9, pp. 1755–1758, 1998.

[6] T. Atsumi, M. Leko, M. L. Bertolaccini et al., “Association of autoantibodies against the phosphatidylserine-prothrombin complex with manifestations of the antiphospholipid syndrome and with the presence of lupus anticoagulant,” *Arthritis and Rheumatism*, vol. 43, no. 9, pp. 1982–1993, 2000.

[7] R. L. Brey, “Management of the neurological manifestations of APS—what do the trials tell us?” *Thrombosis Research*, vol. 114, no. 5-6, pp. 489–499, 2004.

[8] The Antiphospholipid Antibodies in Stroke Study (APASS) Group, “Anticardiolipin antibodies are an independent risk factor for first ischemic stroke,” *Neurology*, vol. 43, no. 10, pp. 2069–2073, 1993.

[9] R. L. Brey, R. D. Abbott, J. D. Curb et al., “β-glycoprotein 1-dependent anticardiolipin antibodies and risk of ischemic stroke and myocardial infarction: the Honolulu Heart Program,” *Stroke*, vol. 32, no. 8, pp. 1701–1706, 2001.

[10] M. L. Bertolaccini, T. Atsumi, T. Koike et al., “Antithrombin antibodies detected in two different assay systems. Prevalence and clinical significance in systemic lupus erythematosus,” *Journal of Thrombosis and Haemostasis*, vol. 93, pp. 289–297, 2005.

[11] S. Tuhrim, J. H. Rand, X. Wu et al., “Antiphosphatidyl serine antibodies are independently associated with ischemic stroke,” *Neurology*, vol. 53, no. 7, pp. 1523–1527, 1999.

[12] V. Toschi, A. Motta, C. Castelli, M. L. Paracchini, D. Zerbi, and A. Gibelli, “High prevalence of antiphosphatidylinositol antibodies in young patients with cerebral ischemia of undetermined cause,” *Stroke*, vol. 29, no. 9, pp. 175–176, 1998.

[13] M. Blank, A. Tincani, and Y. Shoenfeld, “Induction of experimental antiphospholipid syndrome in naive mice with purified IgG antiphosphatidylserine antibodies,” *Journal of Rheumatology*, vol. 21, no. 1, pp. 100–104, 1994.

[14] H. Okuma, Y. Kitagawa, T. Ishikawa, and S. Takagi, “Study of phosphatidylserine-dependent anti-prothrombin antibody in cerebral infarction,” *Internal Medicine*, vol. 48, no. 16, pp. 1351–1355, 2009.

[15] The Antiphospholipid Antibodies in Stroke Study Group, “Clinical and laboratory findings in patients with antiphospholipid antibodies and cerebral ischemia,” *Stroke*, vol. 21, no. 9, pp. 1268–1273, 1990.

[16] S. R. Levine, R. L. Brey, C. L. M. Joseph, and S. Havstad, “Risk of recurrent thromboembolic events in patients with focal cerebral ischemia and antiphospholipid antibodies,” *Stroke*, vol. 23, no. 2, pp. 129–132, 1992.

[17] D. Tanne, L. D’Olhaberriague, A. M. Trivedi, L. Salowich-Palm, L. R. Schultz, and S. R. Levine, “Anticardiolipin antibodies and mortality in patients with ischemic stroke: a prospective follow-up study,” *Neuroepidemiology*, vol. 21, no. 2, pp. 93–99, 2002.